Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Evotec AG

Latest From Evotec AG

Evotec Invests €15m In AI-driven Exscientia

Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.

Artificial Intelligence Business Strategies

AstraZeneca Signs AI Deal To Pursue Novel Parkinson's Drugs

AstraZeneca is the most recent big pharma to team up with an artificial intelligence business – following in the footsteps of Takeda, Johnson & Johnson, Sanofi and GlaxoSmithKline – having signed a drug discovery deal with Boston-based BERG.

Deals Artificial Intelligence

Evotec Rides Megatrend In Outsourced Innovation By Buying Aptuit CRO

Evotec's CEO tells Scrip that by buying the CRO Aptuit his combined group becomes a one-stop-shop for drug makers who are increasingly outsourcing their innovation efforts.

Business Strategies M & A

Topas Bags Big Pharma Partner With Lilly Pact

Eli Lilly is impressed with the privately held German biotech spun out of Evotec which is pursuing a novel liver-based immune tolerance approach.

Deals Immune Disorders
See All

Company Information